These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
3. Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims. Lip GYH; Noxon V; Kang A; Luo X; Atreja N; Han S; Cheng D; Jiang J; Abramovitz L; Deitelzweig S J Thromb Thrombolysis; 2024 Aug; 57(6):1092-1102. PubMed ID: 38698197 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
5. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539 [TBL] [Abstract][Full Text] [Related]
6. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392 [TBL] [Abstract][Full Text] [Related]
9. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. Adeboyeje G; Sylwestrzak G; Barron JJ; White J; Rosenberg A; Abarca J; Crawford G; Redberg R J Manag Care Spec Pharm; 2017 Sep; 23(9):968-978. PubMed ID: 28854073 [TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
12. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Brodie MM; Newman JC; Smith T; Rockey DC Am J Med; 2018 May; 131(5):573.e9-573.e15. PubMed ID: 29175237 [TBL] [Abstract][Full Text] [Related]
13. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611 [TBL] [Abstract][Full Text] [Related]
14. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study. Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030 [TBL] [Abstract][Full Text] [Related]
15. Prognosis of Patients With Ischemic Stroke With Prior Anticoagulant Therapy: Direct Oral Anticoagulants Versus Warfarin. Chun KH; Lee H; Hong JH; Seo KD J Am Heart Assoc; 2024 Aug; 13(15):e034698. PubMed ID: 39101509 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. Rollins BM; Silva MA; Donovan JL; Kanaan AO Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements. Pasciolla S; Zizza LF; Le T; Wright K Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. Martinez BK; Sood NA; Bunz TJ; Coleman CI J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]